Survivors of autologous blood or marrow transplantation (ABMT) are predispo
sed to decreased bone mineral density (BMD), but data are lacking on the in
cidence and risk factors for this condition. Therefore, we measured BMD in
64 of 68 consecutive ABMT survivors (35 men and 29 women) attending the Uni
versity of Toronto ABMT long-term follow-up clinic. Patients were evaluated
a median of 4.2 years (range: 4.9 months-11.4 years) after ABMT. Median ag
e at evaluation was 49.6 years (range: 23.5-68.2 years). At the L4 vertebra
e, 17 (26%) patients (eight men and nine women) had osteopenia and one male
(2%) had osteoporosis. Mean BMD at L1-L4 did not differ from healthy young
adults or age and sex matched controls. At the femoral neck, 30 patients (
46%) (18 men and 12 women) had osteopenia and five (8%) (two men and three
women) had osteoporosis. Mean BMD at the femoral neck was significantly low
er than in healthy young adults and age- and sex-matched controls. By regre
ssion analysis, patients with decreased BMD were older than those with norm
al BMD (P = 0.02). Gender, body mass index, time from BMT to evaluation and
presence of hypogonadism were not associated with decreased BMD. Treatment
of decreased bone density was instituted and follow-up data were obtained
1 year after treatment in 22 of 39 patients with reduced BMD. Nineteen (86%
) patients had stabilization or improvement of their bone density at follow
-up. We conclude that, after ABMT, over half of the patients have evidence
of osteopenia or osteoporosis. Men and women were equally affected. In our
study, only older age at evaluation was predictive for loss of BMD. We reco
mmend the measurement of BMD as an integral component to the follow-up of A
BMT patients.